Hydroxyurea treatment effect on children with sickle cell disease and obstructive sleep apnea

Anthony J. Grady, Jane S. Hankins, Brent Haberman, Robert Schoumacher, Rose Mary Stocks

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background: While hydroxyurea is the mainstay of treatment for many of the comorbidities associated with sickle cell disease, its effect on obstructive sleep apnea has not been fully investigated. The purpose of this project is to help characterize the effects of hydroxyurea on obstructive sleep apnea in children with sickle cell disease and determine its therapeutic role in the condition. Methods: Chart review was conducted on two pediatric patients with sickle cell disease who experienced resolution of obstructive sleep apnea following hydroxyurea administration. Results: After undergoing approximately 11 months of hydroxyurea therapy, sleep apnea symptoms improved and obstructive sleep apnea resolution was confirmed by repeat polysomnography in both cases. This resolution was largely secondary to a reduction in the obstructive component of the apnea hypopnea index, highlighting a previously unreported association. Conclusions: As adenotonsillectomy is associated with significant risks in patients with sickle cell disease, it appears reasonable to consider a period of observation for improvement of obstructive sleep apnea following hydroxyurea administration rather than directly proceeding with surgery.

Original languageEnglish (US)
Pages (from-to)697-701
Number of pages5
JournalSleep and Breathing
Volume21
Issue number3
DOIs
StatePublished - Sep 1 2017

Fingerprint

Hydroxyurea
Sickle Cell Anemia
Obstructive Sleep Apnea
Therapeutics
Polysomnography
Sleep Apnea Syndromes
Apnea
Comorbidity
Observation
Pediatrics

All Science Journal Classification (ASJC) codes

  • Otorhinolaryngology
  • Clinical Neurology

Cite this

Hydroxyurea treatment effect on children with sickle cell disease and obstructive sleep apnea. / Grady, Anthony J.; Hankins, Jane S.; Haberman, Brent; Schoumacher, Robert; Stocks, Rose Mary.

In: Sleep and Breathing, Vol. 21, No. 3, 01.09.2017, p. 697-701.

Research output: Contribution to journalArticle

Grady, Anthony J. ; Hankins, Jane S. ; Haberman, Brent ; Schoumacher, Robert ; Stocks, Rose Mary. / Hydroxyurea treatment effect on children with sickle cell disease and obstructive sleep apnea. In: Sleep and Breathing. 2017 ; Vol. 21, No. 3. pp. 697-701.
@article{781a3c62cc5149b2a35b47342df27183,
title = "Hydroxyurea treatment effect on children with sickle cell disease and obstructive sleep apnea",
abstract = "Background: While hydroxyurea is the mainstay of treatment for many of the comorbidities associated with sickle cell disease, its effect on obstructive sleep apnea has not been fully investigated. The purpose of this project is to help characterize the effects of hydroxyurea on obstructive sleep apnea in children with sickle cell disease and determine its therapeutic role in the condition. Methods: Chart review was conducted on two pediatric patients with sickle cell disease who experienced resolution of obstructive sleep apnea following hydroxyurea administration. Results: After undergoing approximately 11 months of hydroxyurea therapy, sleep apnea symptoms improved and obstructive sleep apnea resolution was confirmed by repeat polysomnography in both cases. This resolution was largely secondary to a reduction in the obstructive component of the apnea hypopnea index, highlighting a previously unreported association. Conclusions: As adenotonsillectomy is associated with significant risks in patients with sickle cell disease, it appears reasonable to consider a period of observation for improvement of obstructive sleep apnea following hydroxyurea administration rather than directly proceeding with surgery.",
author = "Grady, {Anthony J.} and Hankins, {Jane S.} and Brent Haberman and Robert Schoumacher and Stocks, {Rose Mary}",
year = "2017",
month = "9",
day = "1",
doi = "10.1007/s11325-017-1458-9",
language = "English (US)",
volume = "21",
pages = "697--701",
journal = "Sleep and Breathing",
issn = "1520-9512",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Hydroxyurea treatment effect on children with sickle cell disease and obstructive sleep apnea

AU - Grady, Anthony J.

AU - Hankins, Jane S.

AU - Haberman, Brent

AU - Schoumacher, Robert

AU - Stocks, Rose Mary

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Background: While hydroxyurea is the mainstay of treatment for many of the comorbidities associated with sickle cell disease, its effect on obstructive sleep apnea has not been fully investigated. The purpose of this project is to help characterize the effects of hydroxyurea on obstructive sleep apnea in children with sickle cell disease and determine its therapeutic role in the condition. Methods: Chart review was conducted on two pediatric patients with sickle cell disease who experienced resolution of obstructive sleep apnea following hydroxyurea administration. Results: After undergoing approximately 11 months of hydroxyurea therapy, sleep apnea symptoms improved and obstructive sleep apnea resolution was confirmed by repeat polysomnography in both cases. This resolution was largely secondary to a reduction in the obstructive component of the apnea hypopnea index, highlighting a previously unreported association. Conclusions: As adenotonsillectomy is associated with significant risks in patients with sickle cell disease, it appears reasonable to consider a period of observation for improvement of obstructive sleep apnea following hydroxyurea administration rather than directly proceeding with surgery.

AB - Background: While hydroxyurea is the mainstay of treatment for many of the comorbidities associated with sickle cell disease, its effect on obstructive sleep apnea has not been fully investigated. The purpose of this project is to help characterize the effects of hydroxyurea on obstructive sleep apnea in children with sickle cell disease and determine its therapeutic role in the condition. Methods: Chart review was conducted on two pediatric patients with sickle cell disease who experienced resolution of obstructive sleep apnea following hydroxyurea administration. Results: After undergoing approximately 11 months of hydroxyurea therapy, sleep apnea symptoms improved and obstructive sleep apnea resolution was confirmed by repeat polysomnography in both cases. This resolution was largely secondary to a reduction in the obstructive component of the apnea hypopnea index, highlighting a previously unreported association. Conclusions: As adenotonsillectomy is associated with significant risks in patients with sickle cell disease, it appears reasonable to consider a period of observation for improvement of obstructive sleep apnea following hydroxyurea administration rather than directly proceeding with surgery.

UR - http://www.scopus.com/inward/record.url?scp=85009292319&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85009292319&partnerID=8YFLogxK

U2 - 10.1007/s11325-017-1458-9

DO - 10.1007/s11325-017-1458-9

M3 - Article

C2 - 28078488

AN - SCOPUS:85009292319

VL - 21

SP - 697

EP - 701

JO - Sleep and Breathing

JF - Sleep and Breathing

SN - 1520-9512

IS - 3

ER -